Dravet syndrome hits 1 in 15,700 US births and carries one of epilepsy's highest documented SUDEP rates.

Dravet syndrome is a severe developmental and epileptic encephalopathy that begins in the first year of life, typically with prolonged, often fever-triggered seizures in a previously normally developing infant. A US population-based study at Kaiser Permanente Northern California put incidence at 1 per 15,700 births, roughly twice the earlier estimate of 1 in 40,000, with a likely-pathogenic de novo SCN1A mutation identified in six of eight clinical cases, or about 1 in 20,900. All identified infants had febrile seizures, and most had prolonged seizures lasting more than 10 minutes by age one.

The burden extends well beyond seizure count. In a 100-patient cohort followed for a median of 17 years, 17 patients died at a median age of 7; the syndrome-specific mortality rate was 15.84 per 1,000 person-years and the SUDEP rate 9.32 per 1,000, the highest documented for any epilepsy syndrome and far above the roughly 5.1 per 1,000 reported for refractory epilepsy in adults. Near-universal developmental slowing and intellectual disability compound the burden, making Dravet a lifelong, multi-system condition rather than a seizure disorder alone.

Mortality risk, not just seizure count, defines Dravet's true disease burden.

Five questions this report answers:

Q1 - What is the US incidence of Dravet syndrome, and how has genetic testing changed the estimate?

Q2 - What is the seizure, developmental and mortality burden across Dravet's natural history?

Q3 - How does SCN1A confirmation gate access to Dravet-specific therapy?

Q4 - How common is Dravet syndrome in the United States today?

Q5 - What is the SUDEP and mortality risk for Dravet patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #SCN1A #Epilepsy #RareDisease #Pediatrics #USHealthcare

Live report page:  https://axlrx.ai/dravet-syndrome/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Free NHS SCN1A testing confirms 75% of UK Dravet diagnoses, feeding a NICE-sequenced cannabidiol-then-fenfluramine treatment algorithm.

Dravet syndrome is a severe, genetically defined developmental and epileptic encephalopathy, with de novo SCN1A pathogenic variants confirmed in an estimated 80% to 90% of UK cases and clinical molecular confirmation running at roughly 75%. An estimated 400 to 500 patients live with Dravet syndrome in the UK. The NHS Genomic Medicine Service offers SCN1A testing free of charge as part of an epilepsy gene panel to any patient presenting with febrile-seizure-onset epilepsy, with a standard turnaround of 8 to 16 weeks and a fast-track route of under 2 weeks for infantile encephalopathy presentations.

Management runs on a NICE-defined sequence rather than physician discretion: valproate and clobazam first, with sodium-channel blockers contraindicated and documented, then cannabidiol, Epidiolex, NICE TA614 from 2019, added and reassessed at 12 weeks, then fenfluramine, Fintepla, NICE TA887 from 2022, added for inadequate responders. Both agents require prescription through one of 25 NHS Highly Specialised Service paediatric epilepsy centres, and fenfluramine carries a mandatory cardiac monitoring obligation, the Fintepla Cardiac Monitoring Scheme. SUDEP risk of 2% to 18% lifetime is a structural feature of NHS management: NICE guideline NG217 mandates a SUDEP risk discussion at every epilepsy review.

Treatment sequence here follows NICE guidance, not physician discretion.

Five questions this report answers:

Q1 - How does the NHS GMS free SCN1A gene panel shape UK Dravet diagnosis rates?

Q2 - What does the NICE TA614/TA887 cannabidiol-then-fenfluramine sequence mean for positioning a new therapy?

Q3 - How does SUDEP risk factor into UK Dravet commercial and medical-affairs planning?

Q4 - Where is the unmet need in the UK Dravet syndrome treatment pathway?

Q5 - What cardiac monitoring obligation applies to fenfluramine under the Fintepla Cardiac Monitoring Scheme?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #NICE #NHS #Epilepsy #UKHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/dravet-syndrome/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Roughly 14 million US adults are diagnosed with COPD, but the blood eosinophil count now decides who reaches a biologic.

COPD remains one of the largest chronic-disease populations in the United States and a leading cause of death, accounting for the majority of chronic lower respiratory disease deaths and ranking as the fourth leading US cause of death in 2019 per CDC MMWR data. Diagnosed prevalence, though, understates the true burden. National survey data show a substantial fraction of at-risk adults have never received a breathing test, leaving a large undiagnosed pool that never enters the treatment pathway at all.

Diagnosis is spirometric, a post-bronchodilator FEV1/FVC ratio below 0.70, and management is now staged by the GOLD A-E system, which in its 2023 revision replaced the old C and D groups with a single exacerbator group, E. The pivotal shift for commercial strategy is biological: the blood eosinophil count, at or above 300 cells per microliter, is the gate that determines whether an exacerbating patient can reach the first COPD biologic. That single lab value converts a symptom-and-history pathway into a biomarker-stratified one.

A single blood test now gates access to the newest COPD therapy.

Five questions this report answers:

Q1 - How big is the biologic-eligible slice once eosinophil 300+ is layered onto treatment failures?

Q2 - Where does the undiagnosed COPD pool sit in the pathway, and what unlocks it?

Q3 - How does the 2023 GOLD A-E reclassification change escalation to add-on therapy?

Q4 - What is the US COPD epidemiology and treatment pathway, and where does the eosinophil biomarker fit?

Q5 - Why does COPD remain a leading cause of death despite being underdiagnosed nationally?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#COPD #Biologics #Eosinophil #RespiratoryHealth #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/copd/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

HR+/HER2- breast cancer is 68% of US cases, but the 20-30% who recur to metastatic disease define the market.

Breast cancer is the most common non-skin cancer in US women, with the American Cancer Society estimating roughly 317,000 new invasive female cases in 2025. Hormone receptor-positive, HER2-negative disease, meaning ER and/or PR positive with HER2 not overexpressed, is the dominant molecular subtype at approximately 68% of cases per SEER data. The overwhelming majority present as early-stage, endocrine-sensitive disease treated with surgery, radiation, and adjuvant endocrine therapy, and is largely curable. Only about 6% present as de novo stage IV. The metastatic population driving the systemic-therapy market comes mainly from the estimated 20-30% of early-stage patients who later recur.

In the metastatic setting the clinical pathway is defined by biomarker testing layered on top of standard ER/PR/HER2 immunohistochemistry. First line is endocrine therapy, an aromatase inhibitor or fulvestrant, plus a CDK4/6 inhibitor. At progression, molecular testing on tissue or circulating tumor DNA directs the next line: ESR1 mutations, detected in roughly 48% of CDK4/6-pretreated patients in EMERALD, open the door to the oral SERD elacestrant; PIK3CA mutations, in about 40% of HR+/HER2- disease per SOLAR-1, direct patients to alpelisib; AKT-pathway alterations direct patients to capivasertib. Serial genomic testing, not a single line of therapy, structures this pathway.

Recurrence, not incidence, is what defines the treatable market.

Five questions this report answers:

Q1 - How large is the addressable HR+/HER2- metastatic population in the US?

Q2 - Which biomarkers, ESR1 and PIK3CA, must be tested and when along the pathway?

Q3 - How does treatment intent change from early to metastatic disease?

Q4 - What is the US epidemiology and clinical treatment pathway of HR+/HER2- breast cancer?

Q5 - What share of HR+/HER2- patients present as de novo stage IV versus later recurrence?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#BreastCancer #HRPositive #Oncology #PrecisionMedicine #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/breast-cancer-hr-positive-her2-negative/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Cold agglutinin disease affects an estimated 5,000 Americans, and separating primary CAD from secondary cold agglutinin syndrome decides who is even eligible for treatment.

Cold agglutinin disease is a rare autoimmune haemolytic anaemia in which a cold-reactive IgM autoantibody binds red blood cells at low temperatures and activates the classical complement pathway through the C1 complex. Complement C3b opsonization then drives mostly extravascular haemolysis in the liver, producing chronic anaemia, profound fatigue and cold-induced circulatory symptoms. Unlike warm autoimmune haemolytic anaemia, this disease is mediated by IgM and the classical complement pathway, which is why complement-directed therapy, not corticosteroids, became the rational treatment target.

The clinical and commercial population divides into primary CAD and secondary cold agglutinin syndrome. Primary CAD is a distinct clonal, low-grade lymphoproliferative bone marrow disorder producing the pathogenic monoclonal IgM; the syndrome is secondary to infection, B-cell lymphoma or another autoimmune disease. A 2016 to 2023 multi-database US claims analysis estimated incidence at 0.6 to 1.2 per 100,000 person-years and one-year prevalence at 1.4 to 3.1 per 100,000, higher in women and rising with age, an order-of-magnitude prevalent pool of roughly 5,000 patients.

Primary CAD and secondary CAS are the same symptom, different diseases.

Five questions this report answers:

Q1 - What is the size and demographic profile of the US CAD population?

Q2 - How does classical complement activation explain hemolysis in cold agglutinin disease?

Q3 - Where does unmet need remain concentrated after sutimlimab's 2022 approval?

Q4 - How common is cold agglutinin disease across the US population?

Q5 - Why does complement inhibition, not corticosteroids, treat cold agglutinin disease?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ColdAgglutininDisease #CAD #Hematology #RareDisease #AutoimmuneHemolyticAnemia #USHealthcare

Live report page:  https://axlrx.ai/cold-agglutinin-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

  An estimated 100,000 to 150,000 Americans have ATTR cardiomyopathy, yet most remain undiagnosed despite a scan that can confirm it without biopsy.

Transthyretin, or TTR, amyloidosis occurs when TTR tetramers pull apart and misfold into amyloid fibrils that deposit in tissue, producing two distinct diseases. ATTR cardiomyopathy, driven by deposits in the heart muscle, is the larger commercial population; ATTR polyneuropathy, driven by deposits in peripheral nerves, is the historically recognised, nerve-led form. Cardiomyopathy itself splits by genotype: wild-type disease accounts for roughly 80% of cases and predominates in men over 70, while hereditary disease, about 20%, stems from a pathogenic TTR variant, most often V122I in the US, which disproportionately affects people of West African ancestry. Estimates place the US cardiomyopathy population at 100,000 to 150,000 patients, most still undiagnosed.

The real story here is diagnostic, not therapeutic. Technetium-pyrophosphate scintigraphy now allows a non-biopsy diagnosis of ATTR cardiomyopathy, replacing endomyocardial biopsy as the gate into treatment. Echocardiographic clues such as increased wall thickness and apical-sparing strain trigger the scan, and the disease is increasingly recognised as an underdiagnosed cause of heart failure with preserved ejection fraction and of severe aortic stenosis. Tafamidis cut all-cause mortality by 29.5% at 30 months in its pivotal trial, and two oral stabilizers plus three RNA silencers are now approved. With effective treatment already available, the rate-limiting step for the market is finding patients, not treating them.

Finding patients, not treating them, is now the market's real constraint.

Five questions this report answers:

Q1 - How large is the undiagnosed US ATTR-CM pool, and where does scintigraphy screening expand it?

Q2 - How do the ATTR-CM vs ATTR-PN split and wild-type vs hereditary divide segment US patients?

Q3 - Which patients fall into the oral-stabilizer vs RNA-silencer treatment pathway today?

Q4 - How many of the estimated 100,000-150,000 US ATTR-CM patients are actually diagnosed?

Q5 - How is ATTR-CM diagnosed without a biopsy today?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #ATTRCM #RareDisease #Cardiology #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/attr-amyloidosis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

NHS Tc-PYP scintigraphy lifted UK ATTR-CM diagnoses to 2,000-5,000 a year, up from fewer than 500 before the pathway existed in 2021.

Transthyretin (ATTR) amyloidosis develops when the TTR protein destabilizes and deposits as amyloid fibrils in the heart (ATTR-CM) and peripheral nerves (ATTR-PN), occurring in wild-type or hereditary (ATTRv) form. NHS England built a Tc-PYP scintigraphy diagnostic pathway for ATTR-CM in 2021, and roughly 30 NHS scintigraphy centres are now active, with referral running from HFpEF patients showing increased echo wall thickness through cardiac MRI where available to Tc-PYP confirmation at a specialist centre. Estimated UK ATTR-CM incidence has since risen to 2,000-5,000 new diagnoses a year, up from fewer than 500 annually before Tc-PYP existed.

ATTRv, the hereditary form, affects an estimated 1,000-2,000 UK patients. The NHS Genomic Medicine Service offers free TTR gene panel testing for probands with clinical features, and the UK National ATTRv Registry, led by UCL and Queen Elizabeth Hospital Birmingham, tracks approximately 800 patients. Val30Met is the most common variant, concentrated in Portuguese and Brazilian-origin families in the UK, alongside Irish Thr60Ala families. NICE's tafamidis approval (TA696), updated by TA984 in June 2024, remains the step-change commissioning event, while vutrisiran (TA868, published 15 February 2023) was recommended for ATTR-PN with a simple Patient Access Scheme discount.

Diagnosis rose fivefold, but commissioning has to keep pace with identification.

Five questions this report answers:

Q1 - How has the Tc-PYP pathway changed the diagnosed UK ATTR-CM population since 2021?

Q2 - What is the size of the UK ATTRv population, and how does NHS GMS testing identify at-risk families?

Q3 - What does vutrisiran's NICE recommendation (TA868) mean for the ATTR-PN population and specialist centre network?

Q4 - Which family origins carry the Val30Met and Thr60Ala ATTRv variants in the UK?

Q5 - How many NHS scintigraphy centres now confirm ATTR-CM diagnoses across the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #ATTRCM #NICE #NHS #UK #DiseaseLandscape

Live report page:  https://axlrx.ai/attr-amyloidosis/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

Fewer than 1,000 of an estimated 15,000-25,000 GCC ATTR-CM patients are diagnosed, under 5%, largely from missing Tc-PYP scans.

Transthyretin amyloidosis causes progressive deposition of misfolded TTR protein as amyloid fibrils, predominantly affecting the heart in ATTR-CM and, in hereditary forms, the peripheral nerves. The GCC cardiac amyloid landscape mirrors the pre-2019, pre-Tc-PYP Western world: most heart failure with preserved ejection fraction and hypertrophic cardiomyopathy is attributed to the region's high background rates of hypertension and diabetes, without ATTR-specific workup. Tc-PYP scintigraphy is available at fewer than 8 GCC centres and TTR genetic testing at only 3 to 4 reference laboratories, leaving an estimated ATTR-CM burden of 15,000 to 25,000 patients against fewer than 1,000 diagnosed.

The GCC also carries its own hereditary ATTR genetic signature. Alongside the globally recognised Val30Met founder mutation, Arabian Peninsula-specific variants have been documented: Ala97Ser in Saudi kindreds, Glu89Gln in UAE and Omani kindreds, and Thr60Ala in some Bahraini families, producing predominantly cardiac or mixed phenotypes across an estimated 500 to 1,000 GCC ATTRv patients. KFSH&RC maintains the only GCC-wide ATTRv genetic registry. Median diagnostic delay runs four to six years from first heart-failure presentation, moving through a five- to seven-step referral chain, with each step typically adding six to eighteen months before genetic testing is even ordered.

Hypertension and diabetes are absorbing a cardiac amyloid population that goes undiagnosed.

Five questions this report answers:

Q1 - What is the true size of the undiagnosed GCC ATTR-CM population within the HFpEF pool?

Q2 - Which Arabian Peninsula-specific TTR genetic variants are documented in GCC kindreds?

Q3 - Where in the referral pathway does the 4-6 year ATTR-CM diagnostic delay concentrate?

Q4 - What diagnostic and access barriers define the addressable GCC ATTR amyloidosis market?

Q5 - How many GCC centres run Tc-PYP scintigraphy, and what does that capacity gap mean for access?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #Cardiomyopathy #RareDisease #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/attr-amyloidosis/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

16.5 million US adults live with atopic dermatitis, yet only the roughly 40% with moderate-to-severe disease enter the biologic-eligible commercial segment.

Atopic dermatitis is a chronic, relapsing, type 2 inflammatory skin disease driven by a weakened skin barrier and by IL-4, IL-13 and IL-31 cytokine signalling. It affects an estimated 16.5 million US adults, roughly 7% adult prevalence, and more than 9.6 million US children. Diagnosis is entirely clinical since there is no confirmatory lab biomarker, anchored on standard criteria, with severity graded by validated instruments such as EASI, IGA and SCORAD. Endotype heterogeneity across age, ethnicity and skin-barrier gene status increasingly informs which targeted therapy a patient receives.

Severity distribution is the commercial pivot. Most patients have mild disease managed with emollients and topical treatment, while approximately 40% of adults, roughly 6.6 million, have moderate-to-severe disease that topical therapy fails to control, the population eligible for systemic biologics and oral JAK inhibitors. Atopic dermatitis is typically the first step of the atopic march, often preceding food allergy, asthma and allergic rhinitis in children, though recent evidence shows the sequence is not as fixed as once assumed. This moderate-to-severe, topical-refractory segment is where dupilumab's roughly 70% biologic share and the JAK step-edit landscape actually play out.

Only the topical-refractory 40% ever reach a biologic or JAK prescription.

Five questions this report answers:

Q1 - How large is the moderate-to-severe, biologic-eligible US atopic dermatitis population?

Q2 - How is atopic dermatitis diagnosed and severity-graded in US practice?

Q3 - How does the atopic march shape long-term patient segmentation and value?

Q4 - How many US adults and children live with atopic dermatitis?

Q5 - What clinical criteria and severity scores define an atopic dermatitis diagnosis?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#AtopicDermatitis #Eczema #Dermatology #Dupixent #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/atopic-dermatitis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

7.2 million Americans have Alzheimer's dementia, but anti-amyloid therapy reaches only the amyloid-confirmed MCI and mild-dementia window, not the whole population.

Alzheimer's disease is the most common cause of dementia. An estimated 7.2 million Americans aged 65 and older were living with Alzheimer's dementia in 2025, a figure projected to reach nearly 13 million by 2050. A further 22% of adults 65 and older have mild cognitive impairment, the earlier clinical stage from which Alzheimer's dementia typically progresses. The disease is now staged along a continuum, from preclinical and asymptomatic through mild cognitive impairment to mild, moderate and severe dementia, and it is that staging, not the raw prevalence figure, that defines the commercially addressable population.

The two approved disease-modifying therapies are indicated only for the mild cognitive impairment and mild-dementia window, and only in patients with confirmed amyloid pathology. One pivotal trial showed a 27% slowing of cognitive decline at 18 months; another showed 35% slowing in a lower-tau population. Amyloid confirmation is therefore the true gate to therapy, historically through a PET scan or spinal fluid test, and now through the first FDA-cleared blood test, cleared in May 2025, with roughly 92% positive and 97% negative concordance against PET or spinal fluid testing. Scalable blood-based confirmation is the single biggest lever on how many eligible patients actually reach diagnosis.

A blood test, not a new drug, may be Alzheimer's biggest market lever.

Five questions this report answers:

Q1 - How large is the amyloid-confirmed, therapy-eligible US Alzheimer's population?

Q2 - Where are the biomarker-confirmation bottlenecks in the US Alzheimer's diagnostic pathway?

Q3 - How do lecanemab and donanemab differ on efficacy and safety?

Q4 - How many Alzheimer's patients are actually eligible for anti-amyloid therapy?

Q5 - What is the new blood test for Alzheimer's amyloid confirmation?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#AlzheimersDisease #Lecanemab #Donanemab #Neurology #USHealthcare #DiseaseLandscape

Live report page:   https://axlrx.ai/alzheimers-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/